{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T03:27:09Z","timestamp":1792553229035,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiol Ther"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s40119-025-00401-z","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T12:37:47Z","timestamp":1742128667000},"page":"141-159","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["ACEi and ARBs as Primary Prevention of Cancer Therapy-Related Cardiomyopathy in Patients Undergoing Chemotherapy with Anthracyclines: A Systematic Review and Meta-Analysis"],"prefix":"10.1007","volume":"14","author":[{"given":"Wissam","family":"Harmouch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Thakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Dang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelazeem Mohamed","family":"Etewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Suthar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Hayek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wissam","family":"Khalife","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4248-781X","authenticated-orcid":false,"given":"Ayman","family":"Elbadawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,16]]},"reference":[{"issue":"12","key":"401_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1136\/heartjnl-2017-312103","volume":"104","author":"PA Henriksen","year":"2018","unstructured":"Henriksen PA. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. 2018;104(12):971\u20137. https:\/\/doi.org\/10.1136\/heartjnl-2017-312103.","journal-title":"Heart"},{"key":"401_CR2","doi-asserted-by":"publisher","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May\u00a03;145(18):e1033. https:\/\/doi.org\/10.1161\/CIR.0000000000001073] [published correction appears in Circulation. 2022 Sep 27;146(13):e185. https:\/\/doi.org\/10.1161\/CIR.0000000000001097] [published correction appears in Circulation. 2023 Apr 4;147(14):e674. https:\/\/doi.org\/10.1161\/CIR.0000000000001142].\u00a0Circulation. 2022;145(18):e895-e1032. https:\/\/doi.org\/10.1161\/CIR.0000000000001063","DOI":"10.1161\/CIR.0000000000001073"},{"key":"401_CR3","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s40959-019-0054-5","volume":"5","author":"N Bansal","year":"2019","unstructured":"Bansal N, Adams MJ, Ganatra S, et al. Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors. Cardiooncology. 2019;5:18. https:\/\/doi.org\/10.1186\/s40959-019-0054-5.","journal-title":"Cardiooncology"},{"issue":"23","key":"401_CR4","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1161\/CIRCULATIONAHA.106.635144","volume":"114","author":"D Cardinale","year":"2006","unstructured":"Cardinale D, Colombo A, Sandri MT, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114(23):2474\u201381. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.635144.","journal-title":"Circulation"},{"issue":"1","key":"401_CR5","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/2193-1801-2-198","volume":"2","author":"M Dess\u00ec","year":"2013","unstructured":"Dess\u00ec M, Madeddu C, Piras A, et al. Long-term, up to 18\u00a0months, protective effects of the angiotensin\u00a0II receptor blocker telmisartan on epirubin-induced inflammation and oxidative stress assessed by serial strain rate. Springerplus. 2013;2(1):198. https:\/\/doi.org\/10.1186\/2193-1801-2-198.","journal-title":"Springerplus"},{"issue":"2","key":"401_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1007\/s12012-016-9365-z","volume":"17","author":"G Janbabai","year":"2017","unstructured":"Janbabai G, Nabati M, Faghihinia M, Azizi S, Borhani S, Yazdani J. Effect of enalapril on preventing anthracycline-induced cardiomyopathy. Cardiovasc Toxicol. 2017;17(2):130\u20139. https:\/\/doi.org\/10.1007\/s12012-016-9365-z.","journal-title":"Cardiovasc Toxicol"},{"issue":"22","key":"401_CR7","doi-asserted-by":"publisher","first-page":"2859","DOI":"10.1016\/j.jacc.2019.03.495","volume":"73","author":"M Guglin","year":"2019","unstructured":"Guglin M, Krischer J, Tamura R, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. J Am Coll Cardiol. 2019;73(22):2859\u201368. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.495.","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"401_CR8","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1001\/jamaoncol.2016.1726","volume":"2","author":"AH Boekhout","year":"2016","unstructured":"Boekhout AH, Gietema JA, Milojkovic Kerklaan B, et al. Angiotensin\u00a0II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. JAMA Oncol. 2016;2(8):1030\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2016.1726.","journal-title":"JAMA Oncol"},{"issue":"8","key":"401_CR9","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1200\/JCO.2016.68.7830","volume":"35","author":"E Pituskin","year":"2017","unstructured":"Pituskin E, Mackey JR, Koshman S, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol. 2017;35(8):870\u20137. https:\/\/doi.org\/10.1200\/JCO.2016.68.7830.","journal-title":"J Clin Oncol"},{"issue":"21","key":"401_CR10","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","volume":"37","author":"G Gulati","year":"2016","unstructured":"Gulati G, Heck SL, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J. 2016;37(21):1671\u201380. https:\/\/doi.org\/10.1093\/eurheartj\/ehw022.","journal-title":"Eur Heart J"},{"issue":"25","key":"401_CR11","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1161\/CIRCULATIONAHA.121.054698","volume":"143","author":"SL Heck","year":"2021","unstructured":"Heck SL, Mecinaj A, Ree AH, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): extended follow-up of a 2\u00d72 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Circulation. 2021;143(25):2431\u201340. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.054698.","journal-title":"Circulation"},{"key":"401_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"401_CR13","unstructured":"Review Manager (RevMan) [Computer program]. Version 7.2.0. The Cochrane Collaboration, 2024. Available at https:\/\/revman.cochrane.org\/."},{"key":"401_CR14","unstructured":"GRADEpro Guideline Development Tool [Software]. McMaster University and Evidence Prime,\u00a02025. Available from\u00a0https:\/\/www.gradepro.org\/."},{"issue":"11","key":"401_CR15","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1002\/sim.1186","volume":"21","author":"JP Higgins","year":"2002","unstructured":"Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539\u201358. https:\/\/doi.org\/10.1002\/sim.1186.","journal-title":"Stat Med"},{"issue":"7414","key":"401_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/bmj.327.7414.557.","journal-title":"BMJ"},{"key":"401_CR17","unstructured":"Higgins JP, Thomas J, Chandler J, et al., editors. Cochrane handbook for systematic reviews of interventions\u00a0version 6.4\u00a0(updated August 2023). Cochrane, 2023. Available from https:\/\/training.cochrane.org\/handbook."},{"issue":"11","key":"401_CR18","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/ajh.21840","volume":"85","author":"P Georgakopoulos","year":"2010","unstructured":"Georgakopoulos P, Roussou P, Matsakas E, et al. Cardioprotective effect of metoprolol and enalapril in doxorubicin-treated lymphoma patients: a prospective, parallel-group, randomized, controlled study with 36-month follow-up. Am J Hematol. 2010;85(11):894\u20136. https:\/\/doi.org\/10.1002\/ajh.21840.","journal-title":"Am J Hematol"},{"issue":"2","key":"401_CR19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.33963\/KP.15163","volume":"78","author":"A S\u0142owik","year":"2020","unstructured":"S\u0142owik A, Jagielski P, Potocki P, et al. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study. Kardiol Pol. 2020;78(2):131\u20137. https:\/\/doi.org\/10.33963\/KP.15163.","journal-title":"Kardiol Pol"},{"issue":"12","key":"401_CR20","doi-asserted-by":"publisher","first-page":"3964","DOI":"10.1002\/cam4.3956","volume":"10","author":"M Lee","year":"2021","unstructured":"Lee M, Chung WB, Lee JE, et al. Candesartan and carvedilol for primary prevention of subclinical cardiotoxicity in breast cancer patients without a cardiovascular risk treated with doxorubicin. Cancer Med. 2021;10(12):3964\u201373. https:\/\/doi.org\/10.1002\/cam4.3956.","journal-title":"Cancer Med"},{"issue":"8","key":"401_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","volume":"35","author":"SH Armenian","year":"2017","unstructured":"Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2017;35(8):893\u2013911. https:\/\/doi.org\/10.1200\/JCO.2016.70.5400.","journal-title":"J Clin Oncol"},{"issue":"4","key":"401_CR22","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1524-6175.2005.05264.x","volume":"8","author":"SG Chrysant","year":"2006","unstructured":"Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens (Greenwich). 2006;8(4):261\u20138. https:\/\/doi.org\/10.1111\/j.1524-6175.2005.05264.x.","journal-title":"J Clin Hypertens (Greenwich)"},{"issue":"4","key":"401_CR23","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1385\/ct:3:4:319","volume":"3","author":"RJ Boucek Jr","year":"2003","unstructured":"Boucek RJ Jr, Steele A, Miracle A, Atkinson J. Effects of angiotensin-converting enzyme inhibitor on delayed-onset doxorubicin-induced cardiotoxicity. Cardiovasc Toxicol. 2003;3(4):319\u201329. https:\/\/doi.org\/10.1385\/ct:3:4:319.","journal-title":"Cardiovasc Toxicol"},{"issue":"2","key":"401_CR24","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jtcvs.2010.07.097","volume":"142","author":"A Hiona","year":"2011","unstructured":"Hiona A, Lee AS, Nagendran J, et al. Pretreatment with angiotensin-converting enzyme inhibitor improves doxorubicin-induced cardiomyopathy via preservation of mitochondrial function. J Thorac Cardiovasc Surg. 2011;142(2):396-403.e3. https:\/\/doi.org\/10.1016\/j.jtcvs.2010.07.097.","journal-title":"J Thorac Cardiovasc Surg"}],"container-title":["Cardiology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00401-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40119-025-00401-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40119-025-00401-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,17]],"date-time":"2025-05-17T02:48:39Z","timestamp":1747450119000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40119-025-00401-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,16]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["401"],"URL":"https:\/\/doi.org\/10.1007\/s40119-025-00401-z","relation":{},"ISSN":["2193-8261","2193-6544"],"issn-type":[{"value":"2193-8261","type":"print"},{"value":"2193-6544","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,16]]},"assertion":[{"value":"11 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ravi Thakker is an Editorial Board member of Cardiology and Therapy. Ravi Thakker was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Wissam Harmouch, Alexander Dang, Abdelazeem Mohamed Etewa, Krishna Suthar, Salim Hayek, Wissam Khalife, and Ayman Elbadawi have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}